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Preface 
Uterine endometrial stromal sarcomas are very rare; world-wide, we have estimated 
that 1500-2500 new cases occur annually. The World Health Organization (WHO) 
further divides them as Endometrium Stromal Sarcomas, Low Grade (ESS), and 
Undifferentiated Endometrial Sarcomas (UES).The median age of patients is 43 (19-
63) years. More than 90% of patients with ESS survive without recurrence, while UES 
patients have a very poor prognosis.  
Due to the extreme rarity, diagnosis and treatment are hardly standardized 
and often less optimal (apart from in highly specialized very large centers). In 2003, 
the WHO has changed the definition and diagnostic criteria as the pre-2003 criteria 
were not well reproducible. However, even after 2003 most publications have used 
the pre-2003 criteria. Moreover, the WHO-2003 description of the essential criteria 
(different nuclear atypia degrees and necrosis) is not very exact or quantitative and 
does not at all define the diagnostic and prognostic implications of moderate nuclear 
atypia. The scientific basis of the WHO-2003 therefore is weak and knowledge how 
reliable the criteria are for diagnosis, prediction of disease outcome and treatment is 
virtually non-existent. 
Before 2003, 20% to 35% low-grade ESS recurred, but WHO 2003-defined 
low-grade ESS has 10 years’ recurrence rates of less than 10%. With so few 
recurrences, the balance between treatment guaranteeing cure and overtreatment 
(“not too little” or “too much”) becomes increasingly important. However, primary 
treatment practices range from limited surgery only to extensive surgery combined 
with adjuvant chemotherapy and radiotherapy.  
In view of the above mentioned it is therefore of critical importance to validate 
the diagnostic and prognostic value of the WHO-2003 criteria and definitions of ESS-
16 
 
Low grade and Undifferentiated Endometrial Sarcoma, to develop additional accurate 
and reproducible diagnostic criteria and to evaluate how much treatment is needed in 
ESS-low grade. 
17 
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Abstract 
Endometrial stromal sarcoma (ESS) has been traditionally divided into low and high 
grade based on the mitotic activity but in 2003 the World Health Organization 
(WHO2003) has changed the definition. However, since then, many studies still used 
the old criteria and few focused on WHO2003-defined ESS.  
In the first article (Weiwei Feng, Anais Malpica, Stanley J. Robboy, Einar Gudlaugsson, 
Keqin Hua, Xianrong Zhou, and Jan P. A. Baak . Prognostic Value of the Diagnostic 
Criteria Distinguishing Endometrial Stromal Sarcoma from Undifferentiated 
Stromal Sarcoma, Two Entities within the Invasive Endometrial Stromal 
Neoplasia Family. Int J Gynecol Pathol 2013 May; 32(3): 299-306.), the prognostic value 
of the diagnostic criteria distinguishing Endometrial Stromal Sarcoma from 
Undifferentiated Endometrial Stromal Sarcoma was compared. The World Health 
Organization (WHO2003) recognizes three endometrial stromal neoplasms: non-invasive 
endometrial stromal nodule and the two invasive neoplasms, Endometrial stromal Sarcoma 
(ESS) and Undifferentiated Endometrial Sarcoma (UES). Of import, the WHO2003 does 
not define moderate atypia (an important differentiating diagnostic criterion for ESS and 
UES) nor does it discuss its significance. Moreover, studies on reproducibility and 
additional prognostic value of other diagnostic features in large are lacking. Using strict 
definitions, we analyzed agreement between routine and expert-review necrosis and 
nuclear atypia in 91 invasive endometrial stromal neoplasias. The overall 5- and 10-years 
recurrence-free survival rate estimates were 82% and 75%. Necrosis was well and nuclear 
atypia reasonably well reproducible. The 10-year recurrence free survival rates for necrosis 
Absent/Inconspicuous versus Prominent were 89% and 45% (P < 0.001) and for review-
confirmed None/Mild, moderate, severe atypia 90%, 30% and <20% (P <0.00001). 
23 
 
Therefore, cases with Moderate/Severe atypia should be grouped together. Nuclear atypia 
and necrosis had independent prognostic value (Cox regression). Once these features were 
taken into account, no other feature had independent additional prognostic value, including 
the mitotic count. Using “None/Mild atypia, necrosis Absent/Inconspicuous” as ESS, 
versus “Moderate/Severe atypia present or necrosis present” as UES resulted in 68 ESS 
and 23 UES cases with disease specific overall mortality-free survival 99% versus 48%, P 
< 0.00001, HR=45.4). When strictly defined microscopic criteria are used, the WHO2003 
diagnoses ESS and UES are well reproducible and prognostically strong. 
 
In the second article (Weiwei Feng, Keqin Hua, Einar Gudlaugsson, Yinhua Yu, 
Xianrong Zhou, Jan P.A. Baak. Prognostic indicators in WHO 2003 Endometrial 
Stromal Sarcoma, Low Grade. Histopathology. 2013 Apr; 62(5): 675-87), the 
prognosticators in ESS, Low Ggrade were investigated. We reviewed the WHO 
2003diagnostic criteria in 91 tumours (previously classifiedas ESS low and high 
grade). There were 68 cases of ESS-LG and 23 of undifferentiated endometrial 
sarcoma (UES). In the ESS-LG cases, the prognostic value of clinicopathological 
variables was studied. With a median follow-up of 79 months (range: 20–474 
months), the recurrence and death rates were 5/ 68 (7%) and 1/ 68 (1.5%) in the 
ESS-LG cases. Ovarian preservation or no ovarian preservation (P < 0.0001, hazard 
ratio (HR) 10.4) and mitotic activity index (MAI) (0–3 versus >3, P = 0.005, HR 8.6) 
had independent prognostic value. Other frequently used MAI thresholds – age, 
tumour diameter, and vessel invasion – were not prognostic. Among patients without 
ovarian preservation (n = 61), none of 53 with MAI 0–3 suffered recurrence, 
contrasting with two of eight (25%) of those with MAI >3 (P = 0.003); one of these 
two recurrence patients died (P = 0.02). Among patients with ovarian preservation (n 
24 
 
= 7), three (43%) suffered recurrence but none died, and MAI had no additional 
prognostic value. Conclusions: In ESS-LG, ovarian preservation and MAI >3 are 
associated with increased risk of recurrence.  
 
In the third study  (Weiwei Feng, Anais Malpica,  Yu Yinhua,   Emiel Janssen, Einar 
Gudlaugsson,  Xianrong Zhou, Jan P.A. Baak. Diagnostic and prognostic 
morphometric features in WHO2003 invasive Endometrial Stromal Tumours. 
Histopathology. 2013 Apr; 62(5):688-94), the value of morphometric features has 
been evaluated to distinguish mild and moderate atypia in and predict recurrence of 
World Health Organization-2003 defined Endometrial Stromal Sarcomas-Low Grade 
(ESS-LG) and highly malignant undifferentiated uterine sarcomas (UES). Nuclear and 
cytologic size, shape and arrangement were morphometrically evaluated in 41 cases 
with consensus none/mild (n=38) or moderate atypia  (n=3). None of the cases 
showed necrosis. The prognostic value of these features to predict recurrence was 
also assessed. Seven features differed. The mean and standard deviation of the 
nuclear volume and the distance between the nuclei were the best discriminators 
between the non/mild versus moderate atypia, with the maximum of the nuclear 
volume as a practically and rapid evaluable alternative.  Using these features, all mild 
and moderate atypias were correctly classified. Seven cases recurred. The distance 
between the nuclei and percentage of nuclei with one neighbor (assessed with 
morphometric minimum spanning tree analysis) predicted recurrence.  We conclude 
that in invasive endometrial stromal tumours, morphometric features are useful 
diagnostic support tools to distinguish mild from moderate atypia and predict 
recurrence 
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In the fourth study (Weiwei Feng, Anais Malpica, Iva Skaland, Einar Gudlaugsson,  
Stanley Robboy , Keqin Hua, Xianrong Zhou, Jan P.A. Baak. Proliferation biomarkers 
reliably predict recurrence in World Health Organization 2003 defined 
Endometrial Stromal Sarcoma, Low Grade. Manuscript, Submitted February 10, 
2013),the value of proliferation biomarkers predicting  recurrence in WHO-2003 
defined ESS, Low Grade was studied. Using single and multivariate analysis, the 
prognostic value of classical mitosis counts (defined according to the Mitotic Activity 
Index=MAI protocol) in haematoxyllin-eosin (H&E) sections, and 
immunohistochemical proliferation biomarkers (Ki-67 and PhosphoHistone-3 (PPH3)) 
were examined in 24 invasive endometrial stromal sarcomas. Three of 24 (12.5%) 
ESS recurred, of which only one tumor exceeded stage II and stage was prognostically 
not significant. The mitotic count with H&E (MAI), PPH3 and Ki-67 were all 
prognostic (P=0.001, 0.002 and 0.03). MAI is prognostically the strongest 
proliferation biomarker, but can be tedious to reliably assess in poor quality sections. 
PPH3 counts can be easier to perform and closely resemble (but are higher than) the 
true mitoses counts. The fact that Ki-67 is the least prognostic, results from it staining 
not only nuclei in the M(itosis) phase of cycling cells, but also and mostly nuclei of 
proliferating cells in the non-mitotic (G1, S and G2) phases of the cell division cycle, 
many of which likely have genetic damage and die before becoming new daughter 
cells. In conclusion, in WHO2003-defined ESS Low Grade neoplasias, high levels of 
proliferation as measured by MAI, PPH3 and to a lesser degree also Ki-67 are 
predictive of tumors that will recur.  
 
Finally, in the fifth study (Feng Weiwei, Hua Keqin, Malpica Anais, Zhou Xianrong, Jan 
P. Baak). Stages I to II WHO 2003-Defined Low-Grade Endometrial Stromal 
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Sarcoma: How Much Primary Therapy Is Needed and How Little Is Enough? Int J 
Gynecol Cancer. 2013 Mar; 23(3): 488-93.), the effect of different treatment modalities 
was studied.  Before 2003, 20% to 35% low-grade ESS recurred, but WHO 2003-
defined ESS- low-grade has 10 years' recurrence rates of less than 10%. With so few 
recurrences, the balance between treatment guaranteeing cure and overtreatment 
("not too little" or "too much") becomes increasingly important. However, primary 
treatment practices range from limited surgery only to extensive surgery combined 
with adjuvant chemotherapy and radiotherapy. We focused on the primary treatment 
of early-stage WHO 2003-defined ESS, low-grade. The effect of different therapeutic 
strategies was studied in 57 patients with International Federation of Gynecology and 
Obstetrics 2009 stages I to II expert-reviewed WHO 2003-defined ESS, low-grade 
treated at a single institution between 1992 and 2007. The patients' median age was 
43 years (range, 19-63 years). After 68 months' median follow-up (range, 17-140 
months), recurrence and mortality rates were 9% and 2%, respectively. The patients 
with WHO 2003-defined ESS, low grade with ovary-preserving primary surgery had a 
much higher recurrence rate (75%) than those without (2%; P < 0.0001). 
Lymphadenectomy, radical abdominal hysterectomy, and omentectomy did not 
influence survival. Ten patients refused chemotherapy. With univariate analysis, 
multiple-agent chemotherapy improved the prognosis (P = 0.02) With multivariate 
analysis, only ovary preservation-or-not surgery had independent prognostic value. 
We concluded that in International Federation of Gynecology and Obstetrics 2009 
stage I to stage II WHO 2003-defined ESS, low grade, total abdominal hysterectomy 
with bilateral salpingo-oophorectomy is sufficient surgery, but ovary-preserving 
primary surgery increases the risk of recurrence. More extensive surgical procedures 
than total abdominal hysterectomy with bilateral salpingo-oophorectomy do not 
27 
 
improve prognosis. Chemotherapy may improve progression-free survival but a large 
sample size is needed to confirm this. 
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I. Introduction 
 
1. Endometrial stromal Sarcoma and 
Undifferentiated Endometrial Sarcoma 
1.1 General background 
Neoplastic lesions of the uterine endometrium can be of epithelial and mesenchymal 
origin. Cancers are the most frequent. Tumours from the endometrial stroma are less 
frequent and according to the World Health Organization 2003 classification are 
divided into three types: the non-invasive benign stromal nodules, and the invasive 
endometrial stromal sarcomas, low grade (ESS-LG) and undifferentiated endometrial 
sarcomas (UES)1 .  
This thesis will study ESS-LG and UES. ESS-LG is a rare uterine neoplasm 
accounting for 0.2% of all uterine malignancies and 15% of all types of uterine 
sarcomas. However, a higher incidence of 0.7% also has been reported2. UES are 
approximately 5 times less frequent. Based on the numbers in Abeler’s classical 
publication2, the incidence of ESS in Norway (with about 4.5 million inhabitants) can 
be estimated as approximately 2-3 per year.   Koivisto-Korander  reported that the 
incidence rates were about 0.3 per 100,000 for ESS in Denmark, Finland, Iceland, and 
Norway during the study-period (1978-2007)115 .With 650 million inhabitants in the 
Western world, 1.3 billion in China and 1 million in India,  1500-3000 new ESS will 
annually occur worldwide.   
31 
 
 
1.2 Classification of endometrial stromal tumours 
The classification of endometrial stromal tumours (EST) has changed over the past 
two decades. Until the 1980s, ESTs were regarded as benign if the borders were 
smooth, pushy and non-infiltrating and mitoses were few. After the publication of 
Norris et al, in 1966 3, endometrial stromal tumours started to be classified 
according to the number of mitotic figures, with < 10 per 10 high power fields as low 
grade and >=10 as high grade. However, one study4 showed that the reproducibility 
between pathologists in assessing mitosis counts was poor, casting doubt on the 
value of the number of mitotic figures as a single diagnostic criterion.  
In 1982 Evans5 at MD Anderson Cancer Center in Houston proposed a change 
of the paradigm used to approach this disease. Briefly, the paradigm hypothesized 
the existence of two different entities arising from the endometrial stroma: one, 
characterized by the presence of uniform cells resembling the cells of the normal 
proliferative endometrium and a  vascular-rich pattern (endometrial stromal 
sarcoma) and the other characterized by markedly atypical, pleomorphic cells 
lacking the distinct vascular pattern seen in ESS (undifferentiated stromal sarcoma). 
This approach was endorsed by other investigators and ultimately accepted in 2003 
by the World Health Organization classification (WHO2003)1. Benign endometrial 
stromal nodules have a non-invasive pushing border. ESS-LG and Undifferentiated 
Endometrial Sarcomas have invasive borders.  
According to the World health Organization 2003 (WHO2003) classification, 
the term ESS, low grade is used for “endometrial tumours composed of cells 
resembling to those of proliferative phase endometrial stroma. Numerous thin-walled 
arteriolar type (plexiform) vessels are characteristically present. It is distinguished 
32 
 
from the stromal nodule on the basis of myometrial infiltration and/or vascular space 
invasion". Later on, in the histopathology section it says that “by definition, significant 
atypia and pleomorphism are absent” and also: “necrosis is typically absent or 
inconspicuous”. Moreover, it also says: “Although most tumours are paucimitotic, 
mitotic rates of 10 or more than 10 per 10 higher power fields can be encountered, and 
such a higher mitotic index does not itself alter the diagnosis”. “Macroscopically, cystic 
and myxoid degeneration as well as necrosis and hemorrhage are seen occasionally1.  
UES is defined as a high grade endometrial sarcoma that lacks specific 
differentiation and bears no histological resemblance to endometrial stroma. 
Histologically, UES show marked cellular atypia and abundant mitotic activity, often 
including atypical forms. Macroscopically, UES often show prominent hemorrhage and 
necrosis1 Using this newest WHO2003 classification, some tumours previously 
classified as high-grade ESS are now referred to as ESS-LG while others are termed 
UES. Figures 1-3 gives examples of the histopathology of ESS-LG and UES. 
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Figure 1. Endometrial stromal Sarcoma, low grade, with invasive border. 
 
 
Figure 2. Typical vascular pattern of Endometrial stromal Sarcoma, low grade. 
 
 
Figure 3. Severe nuclear atypia of Undifferentiated Endometrial Sarcoma 
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1.3 Confusion in the current WHO 2003 criteria  
          The text of the WHO 2003 clearly indicates that the distinction between ESS-LG 
and UES is no longer based on mitotic activity, but on cellular atypia and necrosis. 
However, the essential features to distinguish necrosis and cellular atypia are rather 
vaguely and not quantitatively defined. What is “inconspicuous” and what is 
“conspicuous” necrosis? As far as we know, a truly scientific analysis of these terms is 
lacking. We assume that “tumor necrosis” is meant, rather than coagulative necrosis, 
but this is also not clearly mentioned. In addition, the WHO2003 does not at all 
describe the significance of moderate atypia, nor is mild and severe atypia exactly 
defined.  
 Finally, the terms ESS-LG and UES in the WHO2003 classification are 
somewhat strange. The addition “low grade” to ESS, suggests that there is also a high 
grade ESS, but this is not further discussed in the WHO2003. This raises the question 
as to the validity of considering UES as an entity distinct from ESS-LG as opposed to 
being one end of the spectrum where  ESS-LG is at the other. By analogy, should grade 
3 endometrial adenocarcinoma be potentially considered as a different entity from 
grade 1 endometrial carcinoma, since both have differing prognoses, even though 
both seem to arise by the same mechanism?  In contrast, molecular evidence now 
points to why borderline serous tumor/grade 1 serous carcinoma of ovary is a 
completely different entity from high grade serous carcinoma as both seem to arise 
by different pathogenetic mechanisms, even though they share many histo-
morphologic features. For example, the former is KRAS & BRAF positive and the latter 
KRAS & BRAF negative. Another issue is whether the WHO2003, in eliminating the 
category high grade ESS, has simply substituted UES in its place (Old dog, new name). 
Or is there a hitherto not described third invasive entity, high grade ESS, in between 
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ESS-LG and UES? Should the category of ESS-high grade be reintroduced if it is shown 
that certain ESS have identifiable criteria associated with a worse prognosis than 
usual for WHO2003 defined ESS-LG, but still differs in some fundamental way so that 
it not can be a subset of the current UES cases?  This is one of the issues we will try to 
answer in the first study described in this thesis. 
In summary, knowledge about reproducibility and validity of diagnostic and 
prognostic criteria for the WHO2003 classification is rather limited and uncertain, as 
the WHO 2003 also acknowledges: “a small minority of cases share features of low 
grade ESS and undifferentiated sarcoma, and their classification is controversial”. We 
therefore set out to study in a large number of WHO2003 defined cases with long 
follow-up the reproducibility and prognostic value of the essential diagnostic features.  
 
1.4 Differential diagnosis 
The distinction of benign endometrial stromal nodule (which is not invasive) 
versus the invasive ESS-LG and UES has been described above in general. The 
WHO2003 microscopic features also have been described. Here follow some more 
specific differential diagnostic remarks. ESS should be distinguished from:  
1. Cellular leiomyoma,  
2. Adenomyosis with stromal predominance and  
3. Adenomyosis with sparse glands.  
Especially important is the differential diagnosis of ESS-LG and common highly 
cellular leiomyoma. We used the following criteria favouring cellular myoma (Table 
1). 
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Table 1. Criteria favouring cellular myoma in the differential diagnosis of Endometrial 
stromal Sarcoma 
1. A fascicular growth pattern,  
2. Large tick-walled vessels,  
3. Merging or slight interdigitation with the adjacent myometrial fascicles,  
4. Presence of cleft-like spaces and  
5. Absence of foamy histiocytes (which are often present in endometrial stromal 
tumours). 
6. CD10 immuno-staining shows strong positivity in ESS vessels but rarely and if 
positive, less intense in cellular myomas. 
 
ESS-LG should be also distinguished from adenomyosis with stromal 
predominance or adenomyosis with sparse glands may be misdiagnosed as ESS-LG. 
Careful sampling usually demonstrates areas of more typical adenomyosis with 
glands. Additionally, in adenomyosis the constituent cells generally appear atrophic 
without mitotic activity, in contrast to the proliferative expansive appearance of the 
stromal cells in ESS-LG where mitotic figures are usually identified6.  
 
1.5 Prognostic factors in ESS-LG and UES 
ESS-LG generally has a good prognosis, with 5- and 10-year actuarial survival for 
patients with stage 1 tumours of 98% and 89%, respectively. However, it has been 
stated by Chang KL that recurrence rates can be as high as 20% of stage 1 tumours 
recur and even more of the stage 2-4 neoplasms7. However, as mentioned before, the 
number of cases studied since the WHO2003 classification was introduced is very 
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limited and we will further study the recurrence rate in our own material in this PhD 
thesis.  
UES has a much worse prognosis, but again no reliable data are available 
because even most of the more recent series of the invasive endometrial stromal 
tumours do not make a distinction between ESS and UES. As the definitions of ESS 
before 2003 and after 2003 are essentially different, studies on prognostic factors 
before 2003 cannot be applied to ESS-LG. A PubMed analysis for ESS articles since 
2003 on the key words “endometrial stromal sarcoma” resulted in nearly 479 hits but 
many of these are case reports which cannot be used for evaluation of prognostic 
factors. Prognostic studies on ESS after 2003 are very rare. Unfortunately, some of 
these studies included various types of uterine sarcomas, but the breakdown of 
results into histological subtypes was either not provided or endometrial stromal 
sarcomas accounted for a small minority of cases and were not separately discussed 8-
15. In others, the old classification as low and high grade endometrial stromal 
sarcomas was still used 16-25.  
In previous studies, many features were prognostic: tumour diameter, 
histologic grade, involvement of surgical margins by tumour, deep myometrial 
invasion, menopausal status, and age 19,20, 7, 26, 27. However, most of these studies were 
published before 2003 and included “ESS high grade” cases which now often (but not 
always) would have been regarded as UES. Only seven other studies evaluated 
prognostic factors in ESS-LG and UES according to the WHO-2003, but the numbers of 
patients studied were small 2, 28-33. Some studies stated that bilateral salpingo-
oorphorectomy does not seem to improve the outcome 21,22, 32,34, but the old 
classification was used in those studies. One study used WHO-2003 criteria showed 
ovary preservation was a risk factor for recurrence 33.  
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Although WHO 2003 does not use mitotic counts as essential diagnostic criteria, 
four studies showed mitotic activity index (MAI) still were prognostic in studies from 
after 2003 2, 28, 116, 117 .  in Abeler’s study 2, the total area at specimen level of the 10 
high power fields used for MAI was 2.8 mm2, much higher than the area widely used 
(1.59 mm2) (see above).  The other  study showed that low mitotic index (MI<5) was 
associated with long disease free survival in ESS, but the clinical significance should 
be further addressed since only 14 cases were included 28. The third study reported 
that survival was significantly longer in the in 21 localized cases (stage I and II) with a 
low mitotic index (P < 0.0001)116. The fourth study showed that there was a 
significant difference in the recurrence rate between cases with different mitotic 
index (≥ 10/10 HPF and < 10/10 HPF, P = 0.009), especially in LGESS group including 
39 cases117.  
Moreover, many studies only did univariate but not multivariate analysis. Thus, 
the knowledge of prognostic factors in WHO2003 defined ESS-LG is limited and their 
value uncertain. The objective of the present study is to further evaluate the 
prognostic value of clinico-pathological variables in a large number of WHO-2003 
defined ESS-LG cases with long follow-up. 
 
1.6 Biomarkers in ESS-LG and UES 
To date, several biomarkers have been studied in endometrial stromal tumors, such 
as  Beta-catenin, P53, WT-1, C-kit, MIB-1, PDGF etc. Since ESS-LG and UES are rare 
tumors, the sample size of those studies is small. But those studies suggest UES and 
ESS-LG have distinct  immunohistochemical and cytogenic profiles. Table 2 gives an 
overview about biomarkers study in Endometrial tumors.  
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Table 2. Overview of biomarkers studies in Endometrial tumors.  
Marker  Year Author Case 
number 
positivity Significance 
Beta-catenin 2009 Kidal35 82ESS, 
18UES 
68% ESS  Nuclear 
expression 
related to 
spread of 
tumor, but not 
related to 
survival. 
2008 Kurihara S36 18 ESS 
7 UES-U* 
6 UES-P* 
47% LGESS 
85% UES-U 
33% UES-P 
 
2010 Kurihara S37 8 ESN, 16 
ESS, 13 
UES 
6/13 UES UES, coincident 
expression of 
beta-catenin 
and cyclin D1 
2008 Jung CK38 2 ESN 
12 ESS 
8 UES 
92% ESS, 
75% UES 
Strong 
expressed in 
67% ESS  
40% UES 
 
2004 Hrzenjak 
A39 
10 ESS  
4 UES 
Increased in 
UES  
 
2005 Nq TL40  40% ESS  
SFRP4 2004 Hrzenjak 
A39 
10 ESS, 
4UES 
decreased in 
10 ESS, more 
lower in 4 
UES 
SFRP4 is a 
putative 
suppressor 
Cyclin D1 2010 Kurihara S37 8 ESN, 16 
ESS, 13 
UES 
2/8 ESN; 
1/17 LGESS, 
6/13 UES 
UES, coincident 
expression of 
beta-catenin 
and cyclin D1 
 2012 Lee CH118 12 
YWHAE-
FAM22 
ESS 
34 JAZF1 
ESS 
21 ESS-LG 
with no 
genetic 
changes 
100% in 
YWHAE-
FAM22 ESS, 
not in other 
ESS 
Cyclin D1 is an 
indicator of 
YWHAE-
FAM22 ESS 
ER, PR 
 
2013 Jakate K119  23 ESS-LG 
10 UES-U 
7 UES-P 
83% ESS-LG 
10% UES-U 
0% UES-P 
 
2008 Kurihara 36 18 ESS 94% ESS,  
40 
 
7 UES-U 
6 UES-P 
57% UES-U, 0 
UES-P 
 
2000 Reich O 44 21 LGESS ER+ 71% 
PR+ 95% 
Hetergenous 
expressin for 
ER PR 
2004 Balleine RL 
41 
9 ESS PRA, PRB 
100%. PRA  
dominant  
 
2003 Popiolek D 
45 
11LGESS 100%  
Aromatase 2004 Reich O42 23 LGESS 83%, high 
expressed in 
22% 
Aromatase 
inhibitor 
treatment 
Estrogen 
sulfotransfe
rase 
2007 Reich O43 29 ESS 5/29    
 2013 Jakate K119 23 ESS-LG 
10 UES-U 
7 UES-P 
0% ESS-LG 
10% UES-U 
57% UES-P 
 
 2012 Park JY120 39 LGESS 10.3% P53 associated 
with poorer 
DFS and OS 
P53 2008 Kurihara 36 18 ESS 
7 UES-U 
6 UES-P 
0 ESS and 
UES-U, 
100% UES-P 
 
2003 Popiolek D 
45 
11LGESS 1/11  
YWHAE-
FAM22 
2012 Isphording 
A121 
6 YWHAE-
FAM22 
ESS 
7 JAZF1-
SUZ12 ESS 
3 JAF1-
PHF1 ESS, 
6 UES 
RT-PCR 
100% in 6 
YWHAE-
FAM22 ESS 
Associate to 
higher grade 
and aggressive 
feature 
MEAF6-
PHF1 
2012 Panagopoul
os I122 
1 ESS with 
recurrence 
  
JAZF1 2013 Jakate K119 23 ESS-LG 
10 UES-U 
7 UES-P 
32% in ESS-
LG , 0% in 
UES 
 
JAZF1-JJAZ1 2008 Kurihara S36 18 LGESS, 
7UES-U, 
6UES-P 
50% LGESS 
1/3  UES-U, 
0/6  UES-P 
UES-p is dffere 
from LGESS 
2011 Amador-
Ortiz C 46 
6 primary 
extra 
uterine 
ESS 
1/6  
2007 Oliva E47 9 ESN, 1 3/6  
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LGESS assessable 
EST+  
2007 Sato K 48 1 
extrauetri
ne ESS  
1 /1   
2007  Nucci MR49 4 ESN, 24 
LGESS 
4/4 ESN  
8/16 ESS  
 
2005 Hrzenjiak A 
50 
20 ESS 2 
UES 
80% ESS  
 0% UES 
 
2006 Micci F51 3 ESS    
2004 Huang Y 52 8 ESS 
4 
metastatic 
ESS 
1 extra-
uterine 
ESS 
2 
recurrent 
ESS 
33% ( 5/15)  
2001 Koontz JI 53 4 ESS  4/4   
PDGFR  2007 Liegl B54 37 c-kit- 
ESS 
PDGFa 65%, 
PDGFβ 0%  
 
PDGFa + ESS 
may benefit 
with tyrosine 
kinase 
inhibitors 
2011 Cheng X 55 13 ESS PDGFa 33% 
PDGFβ36% 
 
 
2007 Adams SF58 42 Uterine 
sarcomas 
PDGFRβ 0%, 
PDGFRα70% 
PDGF-α is a 
potential target 
c-kit  2011 Cheng X 55 13 ESS 8% 
 
 
2008 Zafrakas56 12 uterine 
sarcomas  
Very weak  
2007 Mitsuhashi 
T57 
1 UES  0/1    
2007 Adams SF58 42 uterine 
sarcomas 
10%   
2006 Salvatierra 
A59 
1 HGESS 1/1 Responding to 
Imatinib 
Mesylate( gleev
ec) 
2004 Leath19 3 ESS 3/3  
2006 Nakayama 
M60 
5 ESS 0/5  
2004 Geller20  16 LGESS 
and HGESS 
2/9 LGESS 
5/7 HGESS 
 
2003 Wang L61  11 LGESS 3/11 LGESS  
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3 HGESS 2/3  HGESS 
2003 Rushing 
RS62 
2 ESS, 
2UES  
2/2 ESS 
2/2 UES 
 
2003 Winter 
WE63 
1 ESS 0/1   
2003 Klein WM64 10 LGESS 
2 HGESS 
1/10  LGESS 
0/2  HGESS 
 
MIB 1(Ki-
67) 
2003 Popiolek 
D45  
11LGESS  2/11  
 
MIB1 predict 
LGESS 
recurrence 
2005 Kir G65  8 ESS, 
7ESN 
ESS express 
MIB1 more 
frequenly 
than in ESN  
 
2013 Park JY120 39 LGESS 53.8% Ki-67 
associated with 
poorer DFS and 
OS 
 2013 Jakate K119 23 ESS-LG 
10 UES-U 
7 UES-P 
More 
frequent in 
UES than ESS-
LG 
 
EGFR/ HER-
1 
2012 Capobiano 
G123 
7 ESS-LG 
3 UES  
90% in all 10 
cases 
  
2011 Cheng X 55 13 ESS 0 
 
 
2007 Mitsuhashi 
T57 
1 UES  1/1   
2005 Monifar F 66 20 ESS, 3 
UES 
74%LGESS,  Gefitinib 
therapy 
HER-2 2011 Cheng X 55 13 ESS 0  
2004 Amant F67 21 ESS 
4 UES 
0 in ESS 
1/4 UES 
 
2005 Monifar F 66 20 ESS, 3 
UES 
0  
GnRH I,II 2005 Reich O68 30 ESS Expressed in 
most ESS, 
Recurrence 
stain stronger 
 
VEGF 2011 Cheng X 55 13 ESS 54% 
 
 
WT-1 2007 Coosemans6
9 
15 ESS 7/15   
P16 2013 Iwasaki 
SI122 
4 ESS-LG 
12 UES 
0% in ESS-LG 
83% in UES 
 
Note: *  UES-U: undifferentiated endometrial sarcoma with nuclear uniformity; UES-P: 
undifferentiated endometrial sarcoma with nuclear pleomorphism.  
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1.7 Cytogenetics and Proliferation in ESS 
Among biomarkers listed above, cytogenetics and proliferation markers are 
promising. A variety of cytogenetic abnormalities involving chromosome 7 have been 
reported in endometrial stromal sarcomas. Two zinc finger genes, JAZF1 and JJAZ1, at 
the sites of the 7p15 and 17q21 breakpoints have been identified. The presence of 
JAZF1–JJAZ1 markedly inhibited apoptosis and induced proliferation rates (the latter 
only when normal JJAZ1 was suppressed)53, 70-72. It has been suggested that increased 
cell survival and accelerated cellular proliferation occur upon allelic exclusion of the 
un-rearranged copy of that gene70.  In addition, recently studies suggest a subset of 
endometrial stromal sarcoma harbors t(10;17)(q23;p13), which results in the genetic 
fusion between YWHAE and 1 of 2 highly homologous FAM22 family members - 
FAM22A or  FAM22B. In contrast to classic low-grade ESS with JAZF1-SUZ12 fusions, 
YWHAE-FAM22 ESS displays high-grade histologic features and is associated with 
more aggressive disease course 124, 125. and cyclin D1 can be included in the immuno-
histochemical panel as an indicator of YWHAE-FAM22 ESS118. A novel fusion of 
MYS/Esa1-Associated factor 6 and PHF1 was found in Endometrial Stromal Sarcoma 
126. As most pathology laboratories currently do not have access to translocation 
analysis, and FISH probes for the assessment of JAZF1/JJAZ1 and other fusions are not 
commercially available, it is important to have easy and widely available methods 
allowing pathologists to assess which patients with an ESS are at high recurrence risk. 
Proliferation markers are amongst the most promising. 
 
1.8 Proliferation markers 
Measurement of proliferation by the Mitotic Activity Index is one of the oldest, yet 
still always very useful proliferation biomarkers73-76. However, as we will see in the 
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study on proliferation markers, the methodology in the studies since 2003 has raised 
certain questions, especially reproducibility, which we will try to solve. Others have 
described that c-kit and Ki-67 may have additional prognostic value in ESS, but the 
number of cases studied was small and sometimes before 200319, 20, 45, 55-65. 
Phosphohistone 3, a useful mitosis marker77 showed high inter-observer 
reproducibility and was found prognostically very strong in node-negative breast 
cancer less than 71 years 78, 79. The significance of PPH3 has not been investigated in 
ESS patients. We therefore have analysed in review confirmed WHO2003 ESS, long 
follow-up and known outcome the prognostic value of c-kit, Ki-67 and 
Phosphohistone-3 next to ovary preserving surgery and Mitotic Activity Index. 
 
1.9 Behaviour and treatment of ESS-LG  and UES 
The behavior of ESS-LG is relatively indolent but late recurrence and distal 
metastasis may occur. In contrast, UES is associated with a much worse prognosis. 
Cases with transition of ESS into high-grade sarcoma have been reported 80. Due to its 
rarity, the literature about treatment of ESS-LG and UES is limited both in number of 
articles and number of patients described.  
At the present time, total hysterectomy and bilateral salpingo-oophorectomy, 
with/without lymph-node dissection is recommended by the National 
Comprehensive Cancer Network (NCCN 2011) 81, however, the role of pelvic 
lymphadenectomy is still matter of debate 8, 16-20, 31, 32, 82-88. This is due to the limited 
number of cases of uterine ESS who have received lymphadenectomy as part of their 
treatment in spite of an incidence of nodal metastases that ranges from 0 to 33% 1, 17, 
19, 80, 82-86. In addition, whether bilateral salpingo-oorphorectomy affects outcome in 
early stage ESS is still controversal21, 22, 32-34. Different outcomes of fertility-sparing 
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surgery was revealed by two case reports89,90.   
With regard to adjuvant therapy, several studies have concluded that radiation 
therapy may control local recurrence but does not improve overall survival 16, 19, 20, 80, 
82, 85 while the role of chemotherapy is still unclear 18, 20, 21, 91. Hormone therapy is 
recommended for the treatment of FIGO stages II, III and IV ESS by NCCN, since it was 
reported that LGESS showed 71% positivity for ER and 95% positivity for PR 92. 
Polymorphism 1558 C > T in the aromatase gene may represent a high-risk allele with 
increased local estrogen levels127. 
The use of tamoxifen and HRT is discouraged in ESS 93, whereas progestins, 
aromatase inhibitor letrozole , gonadotropin-releasing hormone-analogues (GnRH-a) 
and mifepristone (RU-486 have been reported to be effective or in clinical trial.32, 94-
96,128. Among these, the usage of progestin could either decrease recurrence rate or 
effectively treat the recurrent ESS-LG patients 129,130. 
As a result, therapies used vary widely from observation without additional 
therapy after limited surgery, to hormonal therapy, chemotherapy and radiation 
therapy, either alone or in varying combinations. Therefore, the roles of extensive 
surgical- and chemotherapy in ESS deserve further attention.  
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I.2. Patients  
 
 
Hospital records of patients diagnosed as endometrial stromal sarcoma between 
1954 and 2007 were retrieved from the Gynecology and Pathology departments of 
Obstetrics and Gynecology Hospital of Fudan University, Shanghai, China. Patient 
records were reviewed for clinico-pathologic variables, surgical management and 
adjuvant therapy, recurrence and patient outcome. Stage was determined according 
to 2009 International Federation of Gynecology and Obstetrics (FIGO) criteria for 
endometrial stromal sarcomas (ESS) and adenosarcomas97. All tissue samples were 
obtained after receiving informed consent, according to institutional rules. Ninety-
eight cases were diagnosed in that time period in our hospital as endometrial stromal 
sarcomas, low or high grade (LGESS, HGESS) according to the old classification. With 
independent review of the original diagnoses by experienced gynaecological 
pathologists, special attention was paid to the differential diagnosis of ESS and 
common highly cellular leiomyoma, as follows. First, we used the following criteria 
favouring cellular myoma; a fascicular growth pattern, large tick-walled vessels, 
merging or slight interdigitation with the adjacent myometrial fascicles, presence of 
cleft-like spaces and absence of foamy histiocytes (which are often present in 
endometrial stromal tumours). Moreover, CD10 immuno-staining was used (showing 
strong positivity in ESS but rarely and if positive, less intense in cellular myomas). 
Doing so, we could not be confirmed at review in 7 consultation cases, leaving 91 
cases. Using the 2003 World Health Organization (WHO2003) classification of 
tumours 68 ESS cases and 23 UES cases were diagnosed.  
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I.3. Methods used 
 
 
3.1 Stage assessment 
Stage was determined using the 2009 FIGO rules for staging of endometrial and 
leiomyosarcomas93,94 (Table 3).  
 
Table 3. The FIGO criteria for staging endometrial stromal  tumours. 
FIGO stage Criterion 
1 Tumor limited to uterus  
2 Tumor extends to the pelvis 
3 Tumor invades abdominal tissues 
4 Tumor invades rectum or bladder, or 
distal metastasis 
   
 
 
3.2 Definition of the microscopic criteria 
Diagnostic criteria per WHO2003 assessed absence or presence of prominent 
necrosis, and the degree of nuclear atypia, which we assessed using the features 
proposed by Kempson and Hendrickson98.  Tumor cell necrosis, as opposed to other 
forms of necrosis, shows a relatively abrupt transition between necrotic and 
preserved cells. The nuclear ghost outlines of the necrotic cells can often be seen 
throughout the necrotic area, and inflammatory cells are uncommon. Necrosis is 
usually conspicuous in UES, the size exceeding more than half of a field of vision with 
a 40 times objective (about 0.4-0.6 mm in diameter).   
Assigning the degree of atypia took into account the degree of nuclear 
pleomorphism, nuclear size, nuclear membrane irregularities, chromatin density, and 
nucleolar size and prominence. Mildly (insignificantly) atypical cells show minimal 
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variation in nuclear size and shape, and nucleoli are small. Moderate atypia (Mod) 
shows scattered pleomorphic nuclei. Severe atypia shows many and severely 
pleomorphic nuclei. Because only few cases showed no nuclear atypia, we grouped 
the atypia as None/Mild. For analysis, we thus distinguished None/Mild, and 
separately moderate and severe atypia (Svr). Although moderate and severe atypia 
were evaluated separately, whenever appropriate they are reported together as 
Mod/Svr.  
Vessel invasion required the presence of tumor cells surrounded by a clear 
space lined with endothelial cells. Shrinkage artifact and true vessel invasion required 
a discrepancy of the shape of the space and the tumour cells. In rare cases of doubt, 
CD10 immuno-histochemistry was used. 
 
3.3 Morphometric methods 
 
In the WHO2003 classification the distinction between ESS and UES is not made on 
the basis of mitotic count but on nuclear pleomorphism and necrosis. Unfortunately it 
can be difficult to reproducibly distinguish between mild and moderate atypia. 
Quantitative pathology aims at obtaining an objective assessment of tumour 
differentiation by measuring cell and tissue characteristics rather than by just giving 
a subjective description. A number of quantitative methods can objectively describe 
the nuclear and cytoplasmic size, shape and arrangement 99. In the present study, we 
set out to evaluate the additional diagnostic and prognostic value of these 
quantitative pathological features in Endometrial stromal Sarcomas and 
Undifferentiated Endometrial Sarcomas.  
 An interactive video-overlay measuring system (QPRODIT®, Leica, Cambridge, 
U.K.) was used for the morphometric analysis. With this system, the microscopic 
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image is recorded by a video camera and displayed on the computer screen. In each 
representative section of the tumour a measurement area, showing the subjectively 
highest degree of atypia was carefully selected and demarcated. The measurements 
were performed in this “measurement area” which was electronically demarcated at 
low magnification (blind re-selection in 10 random cases appeared well 
reproducible). To avoid selection bias and guarantee reproducibility, the nuclear area 
and shape measurements within the measurement area were performed at high 
magnification in 50 fields of vision systematically random spread over the whole 
measurement area. Nuclear morphometry allows for measuring the geometric 
characteristics of the tumour cell nuclei. For nuclear area, size, shape and volume 
measurements, a point grid was superimposed over each measurement area and only 
nuclei hit by one of the points of the point grid were measured. The methodology for 
applying this method has been described in detail before, avoids selection bias and 
increases reproducibility100-102. Information was obtained about the size and shape of 
each nucleus measured.   
The arrangement of the nuclei was analysed with the minimum spanning tree 
(MST). This is a method in syntactic structure analysis that provides quantitative data 
from a microscopic image 103-105. In brief, all nuclei (points) within a certain area of 
tissue are connected by lines, giving a tree figure. The sum of all lines in this tree is 
minimal and there are no loops in it. From this tree we can derive quantitative data, 
such as the average, minimum, maximum, and standard deviation of line length but 
also the number of nuclei connected in the tree with one, two or more neighbours. 
Ten random fields of vision were selected in the tumour areas in each case. The 
centre of each neoplastic nucleus in a field of vision was registered, the minimum 
spanning tree constructed and the quantitative features calculated. Different patterns 
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of nuclear arrangement give different trees and thus different quantitative data about 
the distance and arrangement of the nuclei. With Voronoy’s tessellation, a 
quantitative impression of the cytoplasmic features of the stromal cells was obtained. 
Figure 4 illustrates the morphometric methods. Reproducibility of the quantitative 
pathological features was good, in agreement with previous studies100-105. 
 
 
Figure 4. Examples of the different morphometric methods used. The microscopic 
image is displayed on the screen of the interactive video-overlay measuring system 
(QPRODIT). A. Morphometry of nuclear size and shape. The electronic point grid 
superimposed by QPRODIT hits certain nuclei. To avoid selection bias by the observer, 
only those nuclei can be measured which are hit by such a grid point. Tracing the 
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boundaries results in many quantitative size and shape related quantitative features 
of the nuclei. B. Minimum spanning tree analysis. A minimum spanning tree of 
moderate atypia. Different morphologies give different MSTs, and different 
quantitative data. C. Voronoy tessellation. Using the points placed by the observer in 
the centre of the nuclei, the program equally divides the space between the points. 
The resulting quantitative features of the polygons are then calculated, which are a 
measure of the cytoplasm of the cells. 
 
3.4 Assessment of Mitotic Activity Index (MAI) and vascular invasion 
Although the WHO2003 no longer considers mitotic activity as a diagnostic criterion 
for the distinction of ESS and UES, we still assessed the number of mitoses in 10 fields 
of vision with a 40x objective, field diameter 450 micrometer, numeric aperture 0.65, 
using the MMMCP protocol for counting mitoses 106, which is as follows: 
1. With a black marker on the glass slide, demarcate the most poorly 
differentiated peripheral area of the tumor. Avoid necrotic, heavily inflamed or 
benign areas. This area is called the measurement area of minimally 1x1 and 
maximally 5x5 millimeter. 
2. In the measurement area, at x400 magnification (objective 40, field diameter 
450 μm at specimen level) mitoses are counted in 10 consecutive neighboring 
fields of vision in the most cellular area (representing a total area of 1.59 mm2 
at specimen level). 
3. Only certain mitoses are counted, doubtful structures and apoptotic bodies are 
ignored. The total resulting number of well-defined mitotic figures counted in 
the 10 fields of vision is the Mitotic Activity Index. 
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4. If 2<MAI<6, the MAI was assessed once more, and the highest number of the 
two counts is taken as the MAI. 
An accurate MAI assessment takes 3-5 minutes. Correction of the MAI for the 
percentage of tissue occupied by stroma or the number of tumor cells was not applied 
since it was previously shown that this does not substantially improve the prognostic 
value of the MAI and is  substantially time consuming107,108. Possible error sources 
and alternative mitosis counts methods have been discussed in detail elsewhere.  The 
MAI is not sensitive to fixation delay109, 110. The MAI was well reproducible between 
collaborating laboratories when strictly using the MMMCP protocol106. 
Mitotic activity index (MAI) was defined as the total number of unambiguous 
mitotic figures per 10 high power fields, using a field diameter of 450 micrometer at 
specimen level. This resulted in 1.59 mm2 total section area for 10 fields of vision. The 
sampling and counting protocol was the same as described elsewhere in detail for 
breast cancer111. The counts were made by different pathologists, and again by one of 
us with many years’ experience in mitosis counts (JB, who was blinded to the MAI 
results of the routinely assessed MAI, and also to the original diagnosis, treatment 
and outcome). In case of discrepancy of more than 2 mitoses with the original MAI 
assessment, re-assessment was done by two of us (JB, XZ), using a discussion 
microscope and agreement was always obtained. For vessel invasion we used the 
classical features: tumour cells surrounded by a clear space lined with endothelial 
cells. In order to distinguish between shrinkage artifacts and real vessel invasion, we 
used discrepancy between the shape of the space and the tumour cells. Although 
CD10 alone does not distinguish between endometrial stromal tumors and highly 
cellular leiomyomas, in case of doubt CD10 immunohistochemistry was used to 
further support the histopathological impression. 
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3.5 Immunohistochemistry 
Immunohistochemistry (IHC) was done in twenty-four WHO2003 defined ESS cases. 
Antigen retrieval and antibody dilution were optimized prior to the study onset. To 
ensure uniform handling of samples, all sections were processed simultaneously. 
Four micrometer paraffin sections adjacent to the H&E sections used for histologic 
assessment were mounted onto Superfrost Plus slides (Menzel, Braunschweig, 
Germany) and dried for one hour at 60 oC. Sections were deparaffinized in xylene and 
rehydrated in decreasing concentrations of alcohol. Antigen was retrieved with a 
highly stabilized retrieval system (ImmunoPrep, Instrumec, Oslo, Norway) using 10 
mM TRIS/1 mM EDTA (pH 9.0) as the retrieval buffer. Sections were heated for 3 min 
at 110 oC followed by 10 min at 95oC and cooled to 20º C. All the antibodies are well 
characterized regarding their specificity and sensitivity. The following antibodies 
were used: rabbit polyclonal anti-phosphohistone H3 (ser 10) (clone JBW301, 1:3000, 
Upstate Cell Signaling Solutions, Lake Placid, New York, USA),  Ki-67 (clone MIB-
1,1:50, DAKO, Glostrup, Denmark) was used at a dilution of 1:50, c-Kit (clone CD117, 
dilution 1: 400, DAKO, Glostrup, Denmark). 
Anti-phosphohistone H3 was incubated for 60 min at 22oC. All other antibodies 
were incubated for 30 min at 22oC. Dako antibody diluent (S0809) was used. The 
EnVisionTMFlex detection system (Dako, K8000) was used for visualization of anti-
phosphohistone H3. For Ki-67 the EnVisionTMFlex+ detection system (Dako, K8002) 
was used. Sections were incubated for 5 min. with peroxydase-blocking reagent 
(SM801), 20 min with the EnVision™ FLEX+ Mouse Linker (SM804, only for Ki-67),  
20 min with the EnVision™ FLEX /HRP Detection Reagent (SM802), 10 min with 
EnVision™ FLEX DAB+ Chromogen (DM827)/ EnVision™ FLEX Substrate Buffer 
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(SM803) mix  and  5 min with EnVision™ FLEX Hematoxylin (K8008). The slides were 
dehydrated and mounted. All immunohistochemical stainings were performed using 
a Dako Autostainer Link 48 instrument and EnVision™ FLEX Wash Buffer (DM831).  
 
3.6 Evaluation and reproducibility of Ki-67 and PPH3 
Ki-67 and PPH3 were counted in the same measurement area as described above for 
the MAI (in 10 High Power Fields of vision=HPF, in total 1.59 mm2).  Ki-67 and PPH3 
expressions were defined in two ways:  
1. The total number of positive nuclei and mitoses in 10 HPF, and  
2. The percentage of the positive versus the total number of positive plus negative 
nuclei and mitoses.   
As the results were comparable, only the total number of positive nuclei and mitoses 
in 10 HPF will be further presented.  
To assess inter-observer reliability, the counts were done by two independent 
pathologists (JB, EG) who were unaware of both the clinical outcome and each other’s 
counts results. One pathologist (EG) performed the counts twice, to also assess intra-
observer reproducibility. In order to do an objective quality control as well, Ki-67 was 
also performed using the VIS digital image analysis (DIA) system (Visiopharm, 
Hørsholm, Denmark) with the same image processing principles described before 
(figure 5).  
The reproducibility of the Ki-67 counts by digital image analysis on different 
days by different observers was close to perfect.  The Ki-67 and PPH3 counts of the 
two pathologists correlated reasonably well with each other. Correlation with the 
digital image analysis results (0.61<R<0.69, P < 0.003) was fair, though with a wide 
variation in several cases. 
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The Ki-67 and PPH3 were counted in the same measurement area (10 fields of vision, 
in total 1.56 mm2) described above for the MAI.  Ki-67 was defined as the total 
number of Ki-67 positive nuclei and mitoses, whereas PPH3 was defined as the 
percentage of the PPH3 positive nuclei and mitoses.   
 
Figure 5. Example of PPH3 counting by digital image analysis. (A) Original image. (B) 
Classified image, brown DAB-stained objects are labeled yellow, hematoxylin stained 
objects blue, and background red. (C) Displayed image with counted objects 
surrounded by a blue line. (D-F) details of image processing, metaphase 
chromosomes are fused into one object and small objects are removed. Courtesy: 
Skaland et al, 2008. 
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3.7 Statistics analysis 
SPSS version 15 (SPSS; Chicago, Illinois, USA) was used for the statistical analyses. To 
evaluate the prognostic significance of the variables, univariate (Kaplan-Meier) and 
multivariate (Cox model) survival analysis were performed, using recurrence free 
survival and overall disease related survival as endpoints. MAI and other continuous 
variables such as age were stratified using quartiles and receiver operating curve 
(ROC) analysis (MedCalc, Mariekerke, Belgium) and then tested for their prognostic 
significance. When neighbouring value classes of a variable appeared to have the 
same prognostic value, they were combined to one class. The threshold values for the 
different variables with this method were similar as the ones obtained with ROC 
analysis and only the most important are shown here. P < 0.05 was used as the 
threshold for significant or not. To analyse differences between the different features, 
Student’s t-test or Mann-Witney test was used whichever applicable. With binary 
multiple regression, the independent value of the features was evaluated to 
distinguish the different grades.  
 
 
II Aims of the thesis 
Question to be answered 
The aims of this thesis were to answer the following questions: 
1. What is the reproducibility and prognostic value of the essential diagnostic criteria 
in WHO2003-defined invasive Endometrial Stromal tumours? 
2. What is the value of clinical, therapeutic and histopathological prognostic 
indicators in WHO2003 Endometrial Stromal Sarcoma?  
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3. Do morphometric features have diagnostic and prognostic value in WHO2003 
invasive Endometrial Stromal Tumours? 
4. What is the value of proliferation biomarkers in ESS? 
5. Which Therapeutic Aspects of Endometrial Stromal Sarcoma and Undifferentiated 
Endometrial Sarcoma have prognostic value? 
 
III. Results 
 
Paper 1: Prognostic Value of the Diagnostic Criteria Distinguishing Endometrial 
Stromal Sarcoma from Undifferentiated Stromal Sarcoma, Two Entities within 
the Invasive Endometrial Stromal Neoplasia Family. Int. J Gynecology Pathology. 
2013 May; 32(3): 299-306. 
The World Health Organization (WHO2003) recognizes three endometrial stromal 
neoplasms: non-invasive endometrial stromal nodule and the two invasive neoplasms, 
Endometrial stromal Sarcoma (ESS) and Undifferentiated Endometrial Sarcoma (UES). 
Of import, the WHO2003 does not define moderate atypia (an important 
differentiating diagnostic criterion for ESS and UES) nor does it discuss its 
significance. Moreover, studies on reproducibility and additional prognostic value of 
other diagnostic features in large are lacking. Using strict definitions, we analyzed 
agreement between routine and expert-review necrosis and nuclear atypia in 91 
invasive endometrial stromal neoplasias. The overall 5- and 10-years recurrence-free 
survival rate estimates were 82% and 75%. Necrosis was well and nuclear atypia 
reasonably well reproducible. The 10-year recurrence free survival rates for necrosis 
Absent/Inconspicuous versus Prominent were 89% and 45% (P < 0.001) and for 
review-confirmed None/Mild, moderate, severe atypia 90%, 30% and <20% (P 
<0.00001). Therefore, cases with Moderate/Severe atypia should be grouped 
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together. Nuclear atypia and necrosis had independent prognostic value (Cox 
regression). Once these features were taken into account, no other feature had 
independent additional prognostic value, including the mitotic count. Using 
“None/Mild atypia, necrosis Absent/Inconspicuous” as ESS, versus “Moderate/Severe 
atypia present or necrosis present” as UES resulted in 68 ESS and 23 UES cases with 
disease specific overall mortality-free survival 99% versus 48%, P < 0.00001, 
HR=45.4). When strictly defined microscopic criteria are used, the WHO2003 
diagnoses ESS and UES are well reproducible and prognostically strong.  
Paper 2. Prognostic Indicators in WHO2003 Low Grade Endometrial Stromal 
Sarcoma. Histopathology, 2013 Apr; 62(5): 675-87. 
Endometrial stromal sarcoma (ESS) has been traditionally divided into low/high 
grade but the World Health Organization (WHO2003) has changed the definition. 
Since 2003, many studies still used the old criteria and few focused on WHO2003-
defined ESS low grade (ESS-LG). The prognosticators in ESS-LG were investigated. We 
reviewed the diagnostic WHO2003 criteria in 91 tumours (previously classified as 
ESS low and high grade). There were 68 ESS-LG and 23 UES. In the ESS-LG, the 
prognostic value of clinico-pathological variables was studied. With median follow-up 
of 79 (range: 20-474) months, the recurrence and death rates were 5/68 (7%) and 
1/68 (1.5%) in the ESS-LG. Ovarian preservation or not (P<0.0001, HR=10.4) and 
mitotic activity index (MAI, 0-3 versus >3, P=0.005, HR=8.6) had independent 
prognostic value. Other frequently used MAI thresholds, age, tumour diameter and 
vessel invasion were not prognostic. In patients without ovarian preservation (n=61), 
0/53 with MAI 0-3 recurred, contrasting 2/8 (25%) with MAI>3 (P=0.003) and 1 of 
these 2 recurrence patients died (P=0.02). In patients with ovarian preservation 
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(n=7), 3 (43%) recurred but none died and MAI had no additional prognostic value. 
We conclude that in ESS-LG, ovarian preservation and MAI>3 are associated with 
increased recurrence risk. 
 
Paper 3. Diagnostic and prognostic morphometric features in WHO2003 
invasive Endometrial Stromal Tumours. Histopathology, 2013 Apr; 62(5):688-94. 
The value of morphometric features has been evaluated to distinguish mild and moderate 
atypia in and predict recurrence of World Health Organization-2003 defined Endometrial 
Stromal Sarcomas-Low Grade (ESS-LG) and highly malignant undifferentiated uterine 
sarcomas (UES).  Nuclear and cytological size, shape and arrangement were 
morphometrically evaluated in 41 cases with consensus none/mild (n=38) or moderate 
atypia  (n=3). None of the cases showed necrosis. The prognostic value of these features to 
predict recurrence was also assessed. Seven features differed. The mean and standard 
deviation of the nuclear volume and the distance between the nuclei were the best 
discriminators between the non/mild versus moderate atypia, with the maximum of the 
nuclear volume as a practically and rapid evaluable alternative.  Using these features, all 
mild and moderate atypias were correctly classified. Seven cases recurred. The distance 
between the nuclei and percentage of nuclei with one neighbor (assessed with 
morphometric minimum spanning tree analysis) predicted recurrence. In invasive 
endometrial stromal tumours, morphometric features are useful diagnostic support tools to 
distinguish mild from moderate atypia and predict recurrence.  
 
Paper 4. Proliferation biomarkers reliably predict recurrence in World Health 
Organization 2003 defined Endometrial Stromal Sarcoma, Low Grade. 
Manuscript, Submitted February 10, 2013  
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The value of proliferation biomarkers to predict recurrences in Endometrial stromal 
Sarcoma, low grade, was studied. This rare uterine sarcoma has a relatively indolent 
behaviour but recurrences and distal metastases may occur. Literature about the 
prognostic factors in ESS using the updated definition of ESS is limited. A variety of 
cytogenetic abnormalities involving chromosome 7 have been reported in 
endometrial stromal sarcomas. Two zinc finger genes, JAZF1 and JJAZ1, at the sites of 
the 7p15 and 17q21 breakpoints have been identified. The presence of JAZF1–JJAZ1 
markedly inhibited apoptosis, increased cell survival and accelerated cellular 
proliferation. As most pathology laboratories currently do not have access to 
translocation analysis, and FISH probes for the assessment of JAZF1/JJAZ1 fusion are 
not commercially available, it is important to have easy and widely available methods 
allowing pathologists to assess which patients with an ESS are at high recurrence risk. 
Measurement of proliferation could perhaps be a useful biomarker for this purpose.  
Using single and multivariate analysis, the prognostic value of classical mitosis counts 
(defined according to the Mitotic Activity Index=MAI protocol) in haematoxyllin-eosin 
(H&E) sections, and immuno-histochemical proliferation biomarkers (Ki-67 and 
PhosphoHistone-3 (PPH3)) were examined in 24 invasive endometrial stromal 
sarcomas. Three of 24 (12.5%) ESS recurred, of which only one tumor exceeded stage 
II and stage was prognostically not significant. The mitotic count with H&E (MAI), 
PPH3 and Ki-67 were all prognostic (P=0.001, 0.002 and 0.03). MAI is prognostically 
the strongest proliferation biomarker, but can be tedious to reliably assess in poor 
quality sections. PPH3 counts can be easier to perform and closely resemble (but are 
higher than) the true mitoses counts. The fact that Ki-67 is the least prognostic, 
results from it staining not only nuclei in the M(itosis) phase of cycling cells, but also 
and mostly nuclei of proliferating cells in the non-mitotic (G1, S and G2) phases of the 
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cell division cycle, many of which likely have genetic damage and die before becoming 
new daughter cells. In conclusion, in WHO2003-defined ESS Low Grade neoplasias, 
high levels of proliferation as measured by MAI, PPH3 and to a lesser degree also Ki-
67 are predictive of tumors that will recur.  
  
Paper 5. Stages I to II WHO 2003-Defined Low-Grade Endometrial Stromal 
Sarcoma: How Much Primary Therapy Is Needed and How Little Is Enough? Int J 
Gynecol Cancer. 2013 Mar;23(3):488-93.  the effect of different treatment modalities 
was studied.  Before 2003, 20% to 35% low-grade ESS recurred, but WHO 2003-
defined ESS- low-grade has 10 years' recurrence rates of less than 10%. With so few 
recurrences, the balance between treatment guaranteeing cure and overtreatment 
("not too little" or "too much") becomes increasingly important. However, primary 
treatment practices range from limited surgery only to extensive surgery combined 
with adjuvant chemotherapy and radiotherapy. We focused on the primary treatment 
of early-stage WHO 2003-defined ESS, low-grade. The effect of different therapeutic 
strategies was studied in 57 patients with International Federation of Gynecology and 
Obstetrics 2009 stages I to II expert-reviewed WHO 2003-defined ESS, low-grade 
treated at a single institution between 1992 and 2007. The patients' median age was 
43 years (range, 19-63 years). After 68 months' median follow-up (range, 17-140 
months), recurrence and mortality rates were 9% and 2%, respectively. The patients 
with WHO 2003-defined ESS, low grade with ovary-preserving primary surgery had a 
much higher recurrence rate (75%) than those without (2%; P < 0.0001). 
Lymphadenectomy, radical abdominal hysterectomy, and omentectomy did not 
influence survival. Ten patients refused chemotherapy. With univariate analysis, 
multiple-agent chemotherapy improved the prognosis (P = 0.02) With multivariate 
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analysis, only ovary preservation-or-not surgery had independent prognostic value. 
We concluded that in International Federation of Gynecology and Obstetrics 2009 
stage I to stage II WHO 2003-defined ESS, low grade, total abdominal hysterectomy 
with bilateral salpingo-oophorectomy is sufficient surgery, but ovary-preserving 
primary surgery increases the risk of recurrence. More extensive surgical procedures 
than total abdominal hysterectomy with bilateral salpingo-oophorectomy do not 
improve prognosis. Chemotherapy may improve progression-free survival but a large 
sample size is needed to confirm this. 
 
IV. General Discussion and future directions 
 
 
IV.1. General Discussion 
 
Study 1. Prognostic Value of the Diagnostic Criteria Distinguishing Endometrial 
Stromal Sarcoma from Undifferentiated Stromal Sarcoma, Two Entities within the 
Invasive Endometrial Stromal Neoplasia Family. 
 
The objective of the first study was to evaluate the criteria used by WHO2003 to 
define and distinguish the various groups of malignant endometrial stromal 
neoplasms by evaluating a large cohort of patients with a median follow-up of 5.8 
years (up to 39 years). It was found that the WHO2003 criteria of atypia and necrosis, 
when strictly defined, allow for reliable differentiation of malignant endometrial 
stromal tumours in ESS-LG versus UES as prognostically strong categories. 
Comparison of the original Low/High grade ESS and the WHO2003 diagnoses shows 
that there is moderate agreement only between the two classifications. The WHO 
2003 therefore is not just a name change but results in essential differences in 
diagnosis, prognosis and therefore potentially also treatment. 
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In the WHO2003 description, the definition of ESS is somewhat ambiguous 
(“tumours without significant cellular atypia and pleomorphism”). Usually, most 
pathologists grade nuclear atypia as none, mild, moderate and severe, or as low and 
high. In the WHO2003 description, even though moderate atypia is not discussed, we 
felt it important to determine if this middle category had important prognostic value, 
and what the reproducibility is of these various nuclear atypia grades as well as 
necrosis. Mild (insignificant) atypia showed minimal variation in nuclear size and 
shape, and nucleoli were small.  Quite commonly mild and no atypia were difficult to 
distinguish, and so were combined into a single category. Moderate atypia was 
defined as cases showing scattered pleomorphic nuclei and severe atypia as having 
many and severely pleomorphic nuclei. The absence or presence of prominent 
necrosis also is easily reproducible. Cases with severe atypia are easy to diagnose and 
in our study, half of these cases also had necrosis. Thus, both atypia and necrosis 
proved to be strong independent prognostic indices, but with the incorporation of 
moderate atypia with severe atypia, the prognostic value increased, and when tied 
with prominent necrosis, became the strongest prognostic feature.  Of concern is still 
the potential inter-observer variation in the category of moderate atypia that might 
occur if viewed without strict rules of classification. We have shown in study 3 and 
study 4 of this thesis, that morphometric features and immuno-histochemical 
proliferation biomarkers seem helpful. Until recently, morphometric assessments 
were tedious, but the advent and rapid spread of digital pathology probably will 
drastically change this.  
 In conclusion, the WHO2003 criteria for classifying endometrial stromal 
tumours as ESS versus UES are somewhat ambiguous, but the use of the definitions 
for atypia grades and necrosis result in two prognostically strong and separate 
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categories.  The major distinguishing feature  is atypia that is moderate or severe on 
the one hand versus none or mild on the other. The presence of necrosis is also an 
important independently distinguishing feature. 
 
Study 2. Prognostic Indicators in WHO2003 Low Grade Endometrial Stromal Sarcoma. 
The objective of the second study was to evaluate the prognostic value of clinico-
pathological variables in a large number of WHO-2003 defined ESS-LG cases with 
long follow-up. Our study on 68 WHO-2003 defined ESS is the second largest ever 
done (Abeler et al2 described 85 cases) and also has long-term follow-up. ESS patients 
have good prognosis in general with 2-, 5-, and 10 year disease free survival rates of 
97%, 93% and 93%. However, still a few patients recurred and one died of disease. 
With a generally very favourable outcome in ESS patients, the identification of the 
small number of patients with recurrence is important. Thus, suitable treatments 
could be considered to those identified as high risk patients. We found that ovarian 
preservation was the most important risk factor for recurrence, followed by mitotic 
activity index >3.  
In previous studies, many more features were prognostic: tumour diameter, 
histologic grade, involvement of surgical margins by tumour, deep myometrial 
invasion, menopausal status, and age 19,20, 7, 26, 27. However, these results were either 
based on small number of patients or on univariate analysis only (we used 
multivariate analysis). Moreover, most of these studies were published before 2003 
and included “ESS high grade” cases which now often would have been regarded as 
UES.  
Special attention should be paid here to the classical large clinico-pathological 
study of Chang et al (1990)7, who studied 109 patients with endometrial stromal 
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sarcoma and eight patients with endometrial stromal nodule. Of the 109 patients with 
endometrial stromal sarcoma, follow-up was obtained on 93 (85%). They found that 
36% of the Stage I patients experienced one or more relapses. Of these, 23% died of 
disease from with median follow-up of 79 (range: 11-360) months. Of the 17 stage III 
or IV patients, 13 had one or more relapses and of these, 9 died of disease. The 
outcome differences between Stages I, III, and IV are statistically significant (p< 0.01), 
but neither the mitotic index (number of mitoses/10 high-power fields) and 
cytological atypia were predictive of tumour recurrence for patients with Stage I 
tumours. These results may seem to contradict our results, but this is not supported 
by a closer analysis of the results. The study obviously was many years before the 
WHO 2003 classification was introduced and their definition of ESS was as follows: 
endometrial stromal neoplasms with myoinvasion or intravascular growth. Tumours 
with significant pleomorphism were excluded from the study. As they explicitly 
describe, they found cases with no atypia, mild, moderate and severe atypia, while 
their major break was between no+mild versus moderate+severe atypia. This makes 
clear that the ESS cases they studied included cases that currently would have been 
regarded as undifferentiated endometrial sarcoma. This is further supported by the 
much higher recurrence rates in their stage 1 cases (36%) than in our material. Their 
percentage of stage 3 and 4 cases also was much higher than in our study.  
Total hysterectomy and bilateral salpingo-oophorectomy (BSO) is considered as 
the standard surgical treatment for ESS patients. Several studies challenge the 
inclusion of BSO as standard surgical therapy in patients with disease limited to the 
uterus. Amant et al 32 reported that in stages I–II premenopausal LG-ESS women 
undergoing hysterectomy with or without BSO, relapses occurred in 3 out of 12 (25%) 
and 1 out of 6 (17%), respectively. They stated that BSO does not seem to improve 
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the outcome, but their patient numbers were very small. Kim et al 21 also reported 
that BSO was not correlated with recurrent disease in ESS, but again this study 
evaluated only 22 patients. One case control study by Li 22 carefully compared 12 
LGESS without BSO with 24 LGESS with BSO and found that retention of ovarian 
function (in the absence of metastasis) does not appear to impact risk of recurrence 
or overall survival in stage I LGESS. However, they used a mitotic index<10/10HPF as 
diagnostic criteria which we have shown may have seriously influenced the 
recurrence rate. Moreover, they did not match the tumour size and mitotic count 
between the two treatment groups studied.  
Before 2009, the 1988 FIGO surgical staging system for endometrial cancer was 
recommended for ESS. In 2009, the FIGO committee on Gynecologic Oncology 
introduced a new FIGO staging systems for uterine sarcomas. In the new system, 
stage I and II of the 1988 FIGO staging system have been combined to represent stage 
I ESS. In the current study, we showed that there is no difference in the recurrence 
rates of ESS patients with FIGO-2009 stage I and II (95% and 92%). So, even if the 
disease has spread outside the uterus but still is confined to pelvic cavity, the 
prognosis is good. There was only one stage IV patient in this study, and she died of 
disease, in agreement with the single high stage patient of Abeler et al (2009)2. 
Therefore, distant metastasis in ESS is a very rare event but when it occurs should be 
regarded as an unfavorable prognostic factor.  
We found that the recurrence rate was significantly higher in 7 ESS patients 
with ovary preservation than in 61 patients with ovary castration (43% versus 3%). 
The seven patients with ovary preservation were all stage I and II and relatively 
young with a median age of 35.4 years, whereas the patients without recurrence had 
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a median age of 43 years. Interestingly, the median age in the study of Li et al 
mentioned above was 46 years in both study subgroups23. The variation of recurrence 
rates in women with retained ovarian function may therefore perhaps reflect 
differences in age and different hormonal conditions of the patients with ESS. In 
patients approaching or in the menopause, retention of ovarian function may be of 
less concern for recurrence.  Interestingly, Berchuck et al34 study from 1990 on 
endometrial stromal tumours found that all 6 patients with ESS treated without BSO 
had recurrence, while only 6 of 13 patients treated by TAH–BSO recurred (100% 
versus 43%). Although this finding should be interpreted with care, it thus seems that 
ovarian preservation also increases the recurrence risk in pre- or peri-menopausal 
women with endometrial stromal tumours.  
It is tempting to try to explain this, as follows. Due to their endometrial stromal 
origin, ESSs are oestrogen receptor positive. Ovarian preservation in pre- and to a 
certain degree also in peri-menopausal women results in persistent or occasionally 
high oestrogen levels, which therefore may promote small ER-positive ESS 
metastases. The fact that all ESS patients with recurrence in the present study were 
relatively young (age between 28~43 years) and premenopausal supports this 
hypothesis. The recurrent patients still had an excellent prognosis after resection of 
the metastases and oophorectomy during second surgery. Moreover, there is 
evidence that adjuvant hormonal treatment is beneficial to ESS patients32 and 
pprogestin therapy is currently the most effective treatment for curing and 
preventing local recurrence30. These facts further support the hypothesis of hormone 
dependency of ESS tumours and their recurrence.   
Before 2003, mitotic activity index had a central role in the diagnostic decision 
scheme3 of low grade and high grade neoplasms, but in the WHO2003 it is regarded 
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as unimportant in defining ESS and UES.  The current study shows that most 
(53/68=78%) of the ESS patients without ovarian preservation combined with low 
mitotic activity index (0-3) can be identified as “excellent prognosis”, i.e. unlikely to 
get recurrence (none in our study). On the other hand, those with either ovarian 
preservation, or ovary castration but with MAI>3, have a high risk of 25% to recur. 
What is more, one study showed a trend that low mitotic index (MI<5) was associated 
with long disease free survival in ESS, although only 14 ESS cases were investigated 28. 
These data may give mitotic activity a somewhat important role in the assessment of 
the prognosis of ESS patients.  
Assessment proliferation by MAI can be well reproducible if pathologists 
strictly follow the assessment protocol112. Computerized automated image analysis 
may be of further help to get objective quantifiable support data for the daily work of 
pathologists, as has been shown for other neoplastic organ deviations113. Alternative 
proliferation markers such as MIB-145, c-kit52, and phosphohistone-378, 79 may also be 
important as alternative prognostic markers, as they can ease the work of 
pathologists, be largely automated analysis with excellent reproducibility 114. 
The major strength of our study is that all the ESS cases have been carefully 
reviewed by two experienced pathologists, the number of cases is large and UES cases 
were excluded. The results therefore provide detailed information which may 
valuable when counselling patients with ESS. On the other hand, the limitation of this 
study must also be acknowledged. Only 7 cases received ovary preservation and 5 
cases recurred. Multicentre studies are required to obtain statistically more sound 
results. 
In conclusion, in ESS, ovarian preservation and high mitotic activity should be 
regarded as high risk factors for recurrence.  
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Study 3. Diagnostic and prognostic morphometric features in WHO2003 invasive 
Endometrial Stromal Tumours. 
Study 3 has shown that many features of consensus mild, moderate and severe 
atypias were different with computerized morphometric analysis. Nuclei in moderate 
and severe atypia are generally larger than in mild atypias, but with some overlap. An 
even better discriminator than median nuclear area is the variation in (standard 
deviation of) nuclear area. This makes clear that there are more very large nuclei in 
the moderate/severe atypias, possibly a special cell clone. Moreover, the feature 
CONN1 (describing the number of nuclei connected to one other nucleus only) is 
much higher in mild atypias (figure 2). Combination of the two features gives good 
discrimination. However, in a set for testing, nearly 14% and 17% of the cases is 
misclassified. Therefore the practical value of computerized morphometric analysis 
to support the degree of atypia is limited. 
 We conclude that in endometrial stromal sarcomas, nuclear morphometric 
analysis has limited practical value to support the degree of nuclear atypia. 
 
Study 4.  Proliferation Biomarkers Predict Recurrences in Endometrial stromal 
Sarcoma 
 
A variety of cytogenetic abnormalities involving chromosome 7 have been reported in 
endometrial stromal sarcomas. More specifically, two zinc finger genes, JAZF1 and 
JJAZ1, at the sites of the 7p15 and 17q21 breakpoints have been identified. The 
presence of JAZF1–JJAZ1 markedly inhibited apoptosis, increased cell survival and 
accelerated cellular proliferation. However, most pathology laboratories currently do 
70 
 
not have access to translocation analysis, and FISH probes for the assessment of 
JAZF1/JJAZ1 fusion are not commercially available. It is therefore important to have 
easy and widely available methods allowing pathologists to assess which patients 
with an ESS are at high recurrence risk. Measurement of proliferation could perhaps 
be a useful biomarker for this purpose. We evaluated in 24 review-confirmed 
WHO2003 ESS cases with long follow-up, whether Mitotic Activity Index (MAI), Ki-67, 
PhosphoHistone-3 (PPH3) and c-kit have prognostic value. Three cases recurred, 2 of 
these had ovary preservation surgery (OPS) contrasting 1/22 without OPS 
(P<0.0001). C-kit was negative in all cases. MAI, Ki-67 and PPH3 had prognostic value 
(P=0.001, 0.03 and 0.002, respectively). Two of the 3 recurrent cases had a MAI of 4 
(which were amongst the highest three MAI values found in our series) and also had 
ovary preservation surgery. The third recurrent patient did not have ovary 
preserving therapy but had by far the highest MAI and PPH3 of all ESS tumors. With 
multivariate analysis, OPS was the strongest prognosticator and MAI had 
independent prognostic value. PPH3 also had additional prognostic value to OPS but 
PPH3 was prognostically slightly less strong than the MAI. Therefore, in doubtful 
cases PPH3 can be used as an alternative for the MAI. We conclude that ovary 
preserving primary surgery and proliferation measured by either MAI or PPH3 have 
independent prognostic value in ESS.  
 
 
5. Quality Of Life of Patients with an Endometrial Stromal Sarcoma, Low Grade: how 
much primary therapy is needed and how little is enough?  
The impact of surgical and adjuvant therapies of uterine Endometrial Stromal 
Sarcomas, Low Grade (ESS-LG) defined according to the 2003 World Health 
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Organization classification is controversial. We present our experience with 61 
WHO2003-defined ESS from a consensus expert review of 25 years (1982-2007) at a 
single institution. Seven more cases presented in previous studies were not included 
as they received single agent chemotherapy which is regarded as less effective. We 
recorded   each patient the age, stage of disease according to the FIGO staging system, 
type of surgical treatment, lymph node status, type of chemotherapy regimen if 
applicable and follow-up from the patients’ and pathology charts.  The influence of 
different therapeutic approaches on recurrence and mortality was determined. The 
patients’ median age was 43 (range: 19-63) years. Sixty cases were FIGO stages I-II 
while 1 case was stage IV. After a median follow-up of 72 (range: 20-209) months, 
recurrence and mortality rates were 8% and 2%. ESS patients with ovary 
preservation surgery had a much higher recurrence rate (50%) than those without 
(4%), p<0.0001. Lymphadenectomy, nodal status, radical abdominal hysterectomy 
and omentectomy did not influence survival. Multiple agent chemotherapy improved 
the prognosis (p=0.03) but only ovary preservation-or-not surgery had independent 
multivariate prognostic value. With the exception of the single stage IV patient, all 
other four patients who experienced recurrent disease were alive and well after 
cytoreductive surgery with/without chemotherapy. We conclude that in FIGO stages 
I-II uterine ESS, total hysterectomy with bilateral salpingo-oophorectomy is 
satisfactory therapy. Lymphadenecctomy and extensive surgery do not improve 
survival. Ovary preservation therapy should be avoided.  Recurrent disease can be 
treated effectively with cytoreductive surgery and systemic therapy.  
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IV.2. Future research 
Several issues have not been addressed and beyond the scope of this PhD thesis to 
resolve and remain the subject of future research.   
One is the validity of considering UES as an entity distinct from as opposed to 
being one end of the spectrum where ESS is at the other. By analogy, should grade 3 
endometrial adenocarcinoma be potentially considered as a different entity from 
grade 1 endometrial carcinoma, since both have differing prognoses, even though 
both seem to arise by the same mechanism.  In contrast, evidence now points to why 
borderline serous tumor/grade 1 serous carcinoma of ovary is a completely different 
entity from high grade serous carcinoma as both seem to arise by different 
pathogenetic mechanisms, even though they share many histo-morphologic features. 
For example, the former is KRAS & BRAF positive and the latter KRAS & BRAF 
negative. Issue two is whether the WHO2003, in eliminating the category high grade 
ESS, has simply substituted UES in its place (“Old dog, new name”).  Finally, issue 3: 
should the category of ESS-high grade be reintroduced if it is shown to differ in some 
fundamental way with a subset of the current UES cases? Future studies based on 
immuno-histochemical, molecular pathology and even whole genome sequencing 
may resolve these conundrums. 
As mentioned before, a major strength of our study is that all the ESS and UES 
cases have been carefully reviewed by two experienced pathologists, all patients had 
been diagnosed and treated in one and the same institution and the number of cases 
is relatively large.  
On the other hand, the limitation of this study must also be acknowledged. The 
time between the first and the last diagnosis year (1953-2007) spans more than half a 
century. Only 7 cases received ovary preservation and 5 cases recurred. A second 
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important aspect for future research therefore is to obtain many cases from a limited 
number of years. Multicentre studies are required to obtain statistically more sound 
results. 
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